약물농도를 알 수 없는 환경에서 acetaminophen 급성 중독환자의 안전한 N-acetylcysteine 치료 종료를 위한 혈중약물 검출 예측 = Predicting serum acetaminophen concentrations in acute poisoning for safe termination of N-acetylcysteine in a resource-limited environment

다국어 초록 (Multilingual Abstract)

Purpose: The Prescott nomogram has been utilized to forecast hepatotoxicity from acute acetaminophenpoisoning. In developing countries, emergency medical centers lack the resources to report acetamino phen concentrations; thus, the commencement and cessation of treatment are based on the reporteddose. This study investigated risk factors that can predict acetaminophen detection after 15 hours forsafe treatment termination.
Methods: Data were collected from an urban emergency medical center from 2010 to 2020. The studyincluded patients ≥14 years of age with acute acetaminophen poisoning within 15 hours. The correlationbetween risk factors and detection of acetaminophen 15 hours after ingestion was evaluated using logis tic regression, and the area under the curve (AUC) was calculated.
Results: In total, 181 patients were included in the primary analysis; the median dose was 150.9 mg/kgand 35 patients (19.3%) had acetaminophen detected 15 hours after ingestion. The dose per weight andthe time to visit were significant predictors for acetaminophen detection after 15 hours (odds ratio, 1.020and 1.030, respectively). The AUCs were 0.628 for a 135 mg/kg cut-off value and 0.658 for a cut-off 450minutes, and that of the combined model was 0.714 (sensitivity: 45.7%, specificity: 91.8%).
Conclusion: Where acetaminophen concentrations are not reported during treatment following the UKguidelines, it is safe to start N-acetylcysteine immediately for patients who are ≥14 years old, visit within15 hours after acute poisoning, and report having ingested ≥135 mg/kg. Additional N-acetylcysteine dos es should be considered for patients visiting after 8 hours.

참고문헌 (Reference)

• 1 Department of Health and Human Services, "The new drug application for the use of Acetadote (acetylcysteine) injection" Food and Drug Administration
• 2 Koppen A, "Recommendations for the paracetamol treatment nomogram and side effects of N-acetylcysteine" 72 : 251-257, 2014
• 3 Duffull SB, "Predicting the requirement for N-acetylcysteine in paracetamol poisoning from reported dose" 51 : 772-776, 2013
• 4 University Hospital of Leicester NHS Trust, "Paracetamol poisoning: performa to guide ED management of oral ingestion in adults" University Hospital of Leicester NHS Trust
• 5 University Hospital of Leicester NHS Trust, "Paracetamol poisoning in adults and children" University Hospital of Leicester NHS Trust
• 6 Medicine and Healthcare Products Regulatory Agency, "Paracetamol overdose: simplification of the use of intravenous acetylcysteine" Medicine and Healthcare Products Regulatory Agency
• 7 Lee HS, "Paracetamol elimination in Chinese and Indians in Singapore" 43 : 81-84, 1992
• 8 Department of Health and Human Service, "Intravenous N-acetylcysteine" Food and Drug Administration
• 9 Critchley JA, "Inter-subject and ethnic differences in paracetamol metabolism" 22 : 649-657, 1986
• 10 Jeong HH, "Evaluation of cut-off values in acute paracetamol overdose following the United Kingdom guidelines" 23 : 5-, 2022
• 11 Critchley JA, "Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects" 30 : 179-184, 2005
• 12 Bateman DN, "Acetylcysteine in paracetamol poisoning : a perspective of 45 years of use" 8 : 489-498, 2019
• 13 Rumack BH, "Acetaminophen poisoning and toxicity" 55 : 871-876, 1975
• 14 Rumack BH, "Acetaminophen hepatotoxicity : the first 35 years" 40 : 3-20, 2002
• 15 Rumack BH, "Acetaminophen and acetylcysteine dose and duration : past, present and future" 50 : 91-98, 2012
• 16 Senarathna SM, "A cost effectiveness analysis of the preferred antidotes for acute paracetamol poisoning patients in Sri Lanka" 12 : 6-, 2012